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Introduction: The overlap between asthma and chronic obstructive pulmonary disease (COPD)
(ACO) has been discussed for many years but clinical recommendations for this entity have
been diverse. This study is intended to reach a consensus on diagnosis, treatment and patient
orientation for ACO, within the Portuguese medical community.
Methods: This study was conducted by a multidisciplinary panel of experts from three distinct
medical specialties (Pulmonology, Family Medicine and Immunoallergology). This panel selected
a total of 190 clinicians, based on their expertise in obstructive airway diseases, to participate in
a Delphi structured survey with three rounds of questionnaires. These results were ultimately
discussed, in a meeting with the panel of experts and some of the study participants, and
consensus was reached in terms of classification criteria, treatment and orientation of ACO
patients.
Results: The majority of clinicians (87.2%) considered relevant the definition of an overlap
entity between asthma and COPD. A consensus was achieved on the diagnosis of ACO -- pres-
ence of simultaneous clinical characteristics of asthma and COPD together with a fixed airflow
obstruction (FEV1/FVC < 0.7) associated with 2 major criteria (previous history of asthma;
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presence of a previous history of smoking exposure and/or exposure to biomass combustion;
positive bronchodilation test (increase in FEV1 of at least 200 mL and 12%) on more than
1 occasion) plus 1 minor criteria (history of atopy; age ≥40 years; peripheral eosinophilia
(>300 eosinophils/L or >5% of leukocytes); elevation of specific IgEs or positive skin tests for
common allergens). A combination of inhaled corticosteroid (ICS) with long-acting beta2-agonist
(LABA) or long-acting muscarinic antagonist (LAMA) was considered as first line pharmacological
treatment. Triple therapy with ICS plus LABA and LAMA should be used in more severe or symp-
tomatic cases. Non-pharmacological treatment, similar to what is recommended for asthma
and COPD, was also considered highly important. A hospital referral of ACO patients should be
made in symptomatic or severe cases or when there is a lack of diagnostic resources.
Conclusions: This study highlights the relevance of defining ACO, within the Portuguese medical
community, and establishes diagnostic criteria that are important for future interventional
studies. Recommendations on treatment and patient’s orientation were also achieved.
Introduction
Although asthma and chronic obstructive pulmonary disease
(COPD) are considered distinct obstructive airway diseases,
the coexistence of features of both diseases in the same
patient has been long recognized. In this context, the indi-
vidualization of an entity of overlap between asthma and
COPD has recently been proposed. Several publications from
diverse working groups have proposed different terms and
classification criteria to describe these patients.1--7 How-
ever, none of these terms or criteria has been universally
accepted.
The lack of consensus on how to define and categorize
such an entity of overlap between asthma and COPD limits
the development of prospective studies needed to deter-
mine the optimal approach to these patients.
Some authors have already published a diverse set of
criteria for asthma/COPD overlap. Most can be grouped
by category, such as (1) clinical criteria and related risk
factors, (2) lung function and (3) laboratory data/immune-
inflammatory markers. Among the proposed criteria are: (1)
simultaneous presence of clinical features of asthma and
COPD in the same patient, previous history of asthma or
atopy, current or past history of smoking or biomass combus-
tion exposure, age >40 years-old; (2) presence of persistent
airflow limitation (post-bronchodilator FEV1/FVC < 0.7), pos-
itive or very positive response to the bronchodilator test
(FEV1 increase of at least 200 mL and 12% or at least 400 mL
and 15%, respectively), presence of bronchial hyperrespon-
siveness; (3) peripheral eosinophilia (>300 eosinophils/L or
>5% of the total leukocytes), sputum eosinophilia, elevation
of the fractional exhaled nitric oxide (FENO) and eleva-
tion of total serum immunoglobulin E (total IgE).1--7 In fact,
our group carried out a review of the main definitions and
diagnostic criteria which was published recently,8 in addi-
tion, in this paper a proposal of recommendations adapted
to the Portuguese situation was achieved by a group of
respiratory disease experts. In order to obtain a broader
consensus, a larger study was needed, leading to the present
project.
Objectives
The main aims of this project, intended to be adapted and
applied in Portuguese clinical practice, were:
1. to assess the need for the recognition of an overlap
entity between asthma and COPD within the Portuguese
medical community who treat patients with respiratory
diseases;
2. to achieve consensus over terminology and classification
criteria for such an entity;
3. to achieve consensus on the approach and adequate ori-
entation of these patients.
Methods
This study was conducted by a multidisciplinary panel
of experts from three distinct medical specialties: Pul-
monology, Family Medicine and Immunoallergology.
A committee panel was created with elements from the
three specialties described above. This committee selected
a total of 190 members from the three medical special-
ties -- Pulmonology (n = 85), Family Medicine (n = 62) and
Immunoallergology (n = 43) -- to participate in the ques-
tionnaires based on their expertise in obstructive airway
diseases.
The study followed a Delphi structure with three rounds
of questionnaires. The first questionnaire was mainly com-
posed of open-ended questions in order to obtain meaningful
answers that reflect the overall non-conditioned opin-
ion of the participants. A classical content analysis was
endorsed, organized by tabulating records with the fre-
quency of freely elicited ideas. The results were discussed
within the scientific board of a multidisciplinary panel of
experts and the subsequent survey was drawn up based
on the answers obtained in the first round, the same
process was used for the final questionnaire. The second
questionnaire was intended to be the cornerstone of the
inquiry, containing a detailed and wide range of questions
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comprising nomenclature and the three main domains of
the diagnostic criteria (clinical, lung function and laboratory
data/immune-inflammatory markers), as well as treatment
approach and orientation of the patients. The third ques-
tionnaire aimed at clarifying any topic that had not been
fully established in the preceding round or any doubt that
had arisen in the discussion of the data obtained previously.
The answers were not conditioned in any way, even if only
theoretically. Previously existing ideas and concepts were on
the basis of this consensus survey.
These questionnaires were inserted into an online plat-
form specifically created for this study. A link to this
platform was sent via electronic mail to the clinicians who
answered anonymously and with a user sensitive and con-
fidential password to provide access to the platform. The
clinicians were allowed to answer each questionnaire in
stages; they did not need to answer everything at once.
Answering time ranged from minutes to two weeks, so
that the participants had enough time to think about their
answers, which did not force a pattern of only immediate
opinions.
After the application of the questionnaires, a final meet-
ing took place, involving the committee panel and some of
the respiratory experts that had participated in this study,
in which the results were discussed and a consensus was
obtained in terms of classification criteria, treatment and
orientation of ACO.
Results
Each step of the Delphi had a different number of respon-
ders, the first questionnaire having the lowest participation
(Table 1).
First questionnaire
We received 47 answers to the first phase questionnaire.
The clinicians had a mean (±standard deviation) age of 46.5
(±10) years and 57.4% were female. There was a reasonable
participation by each medical specialty (Table 1).
The purpose of the first question was to assess if the par-
ticipants agreed on the existence of an entity of asthma and
COPD overlap. The majority of the clinicians (87.2%) con-
sidered that it was necessary to identify such an overlap
entity. Only six participants considered that there was no
such need.
Those who agreed with the recognition of a distinct entity
of overlap between asthma and COPD were asked to propose
a designation for that entity. Two terms stand out from the
proposals: asthma-COPD overlap syndrome (ACOS), n = 15,
and asthma-COPD overlap (ACO), n = 12. Other designations
were proposed, but were not considered to be relevant since
each of them was only supported by a residual number of
participants.
The participants were also asked if the information in the
medical literature was sufficient for identifying the over-
lap entity and the majority (85.1%; n = 40) considered that
currently available information was insufficient.
The participants were then requested to propose essen-
tial criteria to define the overlap between asthma and
COPD entity. A variety of criteria were suggested and these
were divided into 3 categories: clinical, lung function and
laboratory data/immune-inflammatory markers. The most
relevant clinical criteria for the participants were: pre-
vious history of asthma, age, clinical features of asthma
and COPD, exposure to tobacco smoking or to biomass
combustion and atopy. In terms of lung function, clinicians
considered that spirometry should be taken into account,
considering as criteria the presence of fixed obstruction,
obstruction with partial reversibility, positive bronchodila-
tor response and also a positive bronchodilator response in a
COPD patient and poor reversibility in an asthmatic patient.
In terms of criteria related to laboratory data/immune-
inflammatory markers, peripheral eosinophilia was the one
most frequently suggested.
Forty clinicians (85.1%) considered that the identifi-
cation of this entity of overlap had distinct therapeutic
implications from those generally adopted in asthma
and COPD. The orientation suggested by the participants
was divided into pharmacological and non-pharmacological
measures. Regarding pharmacological treatment, most sug-
gested inhaled corticosteroid (ICS) in association with
long-acting beta2-agonist (LABA) or long-acting muscarinic
antagonists (LAMA) (50.0%) and triple therapy with ICS,
LABA and LAMA (29.2%). Other measures clinicians consid-
ered important were the control of risk factors, such as
smoking cessation, ensuring effective vaccination coverage
for flu and pneumococcus, the treatment of comorbidities,
implementation of a pulmonary rehabilitation program and
allergenic eviction.
This first questionnaire was thus answered by a reason-
able number of participants of each medical specialty. The
answers were almost unanimous, they considered that it was
necessary to identify an entity of overlap between asthma
Table 1 Total participants and their basic characterization, by questionnaire.
1st questionnaire 2nd questionnaire 3rd questionnaire
Total participants (n) 47 88 104
Age (mean ± SD), years 46.5 (±10.5) 46.4 (±10.8) 46.2 (±11.1)
Gender Male (%) 42.6 52.3 51.0
Female (%) 57.4 47.7 49.0
Medical speciality Pulmonology (n) 12 27 28
Family medicine (n) 15 26 37
Immunoallergology (n) 20 35 39
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and COPD and that the literature available about this issue
was not sufficient. Moreover, most of them considered that
the recognition of this entity of overlap implied a distinct
therapeutic approach. This supported the following steps of
our work, leading to the following rounds of questionnaires.
These were mainly composed of close-ended questions, tak-
ing into account the answers obtained from the previous
questionnaire.
Second questionnaire
The second questionnaire was answered by 88 clinicians with
a mean (±SD) age of 46.4 (±10.8) years and rather homoge-
nous distribution between the three medical specialties that
were consulted -- Immunoallergology (n = 35), Pulmonology
(n = 27) and Family Medicine (n = 26).
In this questionnaire, the majority of physicians sur-
veyed answered all the questions, which means that the
interpretations that are made are effectively derived from
the universe of physicians surveyed. Globally, medical spe-
cialties did not differ substantially between each other
regarding the clinical approach to this entity.
The first question was how to describe the overlap entity
between asthma and COPD better. Only 3.4% of the par-
ticipants answered that there was no need for a definition
because they believed the entity did not exist. The major-
ity chose between the two options that were provided --
Asthma-COPD overlap syndrome (ACOS) and Asthma-COPD
overlap (ACO) -- with almost identical numbers between the
two -- 48.9% vs. 46.6%, respectively.
One of the most important topics analyzed in this ques-
tionnaire was the relevance attributed by the clinicians to
the several diagnostic criteria presented.
The diagnostic criteria were divided into three groups
-- clinical, lung function and laboratory data/immune-
inflammatory markers.
Clinicians were asked to rate, on a scale of 1--10, each
criterion in terms of its clinical relevance. Scores ≥7 were
considered highly relevant.
The majority of the clinicians considered the presence of
simultaneous clinical characteristics of asthma and COPD in
the same patient (88.6%) to be highly relevant to the clin-
ical criteria. The presence of a previous history of asthma
(72.7%) and presence of a smoking history (76.1%) were also
criteria where a significant consensus on high relevance was
met. On the other hand, other criteria such as a previous
history of atopy, exposure to biomass fuel combustion, and
age ≥40 years, met with more diverse opinions (percentage
of highly relevant considerations: 46.6%, 63.6% and 65.9%,
respectively).
Regarding lung function criteria, almost all the clini-
cians think that the presence of fixed airflow obstruction
(FEV1/FVC < 0.7) is highly relevant (84.1%). A positive
bronchodilatation test and a definition of positive bron-
chodilation test characterized by an increase in FEV1 of at
least 200 mL and 12% were also considered to be of great
importance (85.2% and 64.8%, respectively). A positive bron-
chodilation test on more than one occasion was a criterion in
which there was a more heterogenic pattern of answers (only
42.1% considered it highly relevant). A very positive bron-
chodilation test with an increase in FEV1 of 400 mL and at
least 15% and the presence of bronchial hyperreactivity did
not achieve the same consensus (26.1% and 36.4%, respec-
tively, considered it highly relevant). Family Medicine gave
greater importance to bronchial hyperresponsiveness than
did Pulmonology and Immunoallergology (Sig 2 = 0.055),
although this was not an indisputable differentiation, it was
at least a strong trend.
None of the laboratory data/immune-inflammatory
markers, (peripheral eosinophilia, total IgE, FENO, and spe-
cific IgEs) achieved a significant degree of consensus in terms
of degree of importance (39.8%, 18.2%, 25.0% and 35.2%
considered it highly relevant, respectively).
Another of the questions concerned the definition of the
overlap entity using major and minor criteria. The majority
of the clinicians (75.2%) agreed with this approach.
With regard to treatment, clinicians were asked which
should be the first line of treatment. Most of them chose
the ICS plus LABA and/or LAMA (69.3%), or ICS plus LAMA
and/or LABA (22.7%). Although the majority of participants
from the different medical specialties considered the associ-
ation of ICS plus LABA and/or LAMA as the most appropriate
as a first line treatment, Family Medicine participants dif-
fered from the other participants, with almost half of them
considering the association between ICS plus LAMA as a first
line treatment (Sig 2 = 0.025).
The clinicians were asked about other non-
pharmacological therapeutic measures they thought
should be applied in patients with this overlap entity.
Almost all of them considered an encouragement of thera-
peutic adherence (94.3%), a verification of the inhalation
technique (100%) and comorbidities treatment (92%) as key
measures to adopt.
Other measures such as smoking cessation (97.7%),
pulmonary rehabilitation (78.4%), and pneumococcal and
influenza vaccination (96.6%) were also considered highly
relevant.
Clinicians were divided over where the initial medi-
cal diagnostic approach should be performed, whether in
a specialist hospital clinic (45.5%) or in primary health-
care (52.3%). The follow-up of these patients should be
performed, according to the clinicians, first in a special-
ist hospital clinic and then in articulation with primary
care (47.7%), or in the hospital only in the case of a
non-controlled patient (44.3%). On this point, a significant
difference in the pattern of approach was noted between
medical specialties. Pulmonologists and Immunoallergolo-
gists most frequently considered that the initial approach
should be performed in a specialized hospital clinic while
Family Medicine participants considered they had suffi-
ciently good conditions and the knowledge to perform the
diagnosis of ACO with a high degree of autonomy, suggest-
ing that they should be responsible for this first step (Sig
2 < 0.01). A similar pattern was observed in relation to
patient follow-up (Sig 2 = 0.005).
Third questionnaire
The third questionnaire was answered by 104 clinicians,
with a mean (±SD) age of 46.2 (±11.1) years and 51% were
male. There was an almost homogenous distribution by the
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three medical specialties: Immunoallergology, n = 39, Family
Medicine, n = 37 and Pulmonology, n = 28.
This questionnaire was entirely made up of close-ended
questions, taking into account the answers obtained from
the previous questionnaires. The first questions intended to
reach a consensus on which criteria should be considered
for the diagnosis of the entity of overlap and specifically
if each criterion should be considered as major or minor.
Criteria that were considered highly relevant in the previous
questionnaire were included in this round. Those criteria
with heterogeneous answers were also included to try to
achieve a better clarification.
Concerning the clinical criteria, it was almost unanimous
(87.5%) that the presence of simultaneous clinical charac-
teristics of asthma and COPD in the same patient should be
considered a major criterion (vs. 8.7% considering it as a
minor criterion and only 3.8% answering that it shouldn’t be
considered as a criterion). Two other clinical criteria were
also classified as major criteria, though not with such an
expressive concordance: the presence of a previous history
of asthma (69.2 vs. 28.8% considering it as a minor criterion)
and the presence of a previous history of smoking expo-
sure and/or exposure to biomass fuel combustion (72.1 vs.
26% considering it as a minor criterion). For each of these
criteria only 1.9% of the participants answered that these
should not be considered as criteria. The remaining clinical
criteria, history of atopy and age ≥40 years, were consid-
ered as minor criteria by the clinicians (69.2% and 49%,
respectively). For these two last criteria, a higher number of
participants did not agree with its inclusion (7.7% and 11.5%,
respectively).
In terms of functional criteria, most of the clinicians
(83.7%) considered the presence of fixed airflow obstruction
(FEV1/FVC < 0.7) as a major criterion (vs. 10.6% consider-
ing it as a minor criterion and only 3.8% of the participants
answering that it should not be considered as a criterion). A
positive bronchodilation test, characterized by an increase
in FEV1 of at least 200 mL and 12%, was also classified as a
major criterion by 53.8% of the clinicians (vs. 37.5% consid-
ering it as a minor criterion and 7.7% participants answering
that it should not be considered as a criterion).
All laboratory data/immune-inflammatory markers were
considered as minor criteria by the majority of the
participants: peripheral eosinophilia, defined as >300
eosinophils/L or >5% of leukocytes (54.8 vs. 15.9% consid-
ering it as a major criterion), elevation of total IgE (53.8 vs.
3.8% considering it as a major criterion), elevation of FENO
(51.0 vs. 5.8% considering it as a major criterion), elevation
of specific IgEs or positive skin tests for common allergens
(59.6 vs. 10.6% considering it as a major criterion). Also, all
of these criteria had a significant number of participants dis-
agreeing with their inclusion as criteria (respectively, 26.9%,
39.4%, 36.5% and 28.8%).
Most of the clinicians considered the presence of at least
2 major and 1 minor criteria (72.1%) as the minimum number
of criteria needed for the diagnosis of the overlap entity.
In relation to the periodicity of the clinical evaluation,
the majority of the clinicians (83.7%) considered that this
should be performed every 3 to 6 months in the early phase,
and then adapted to the patient’s clinical severity/control.
The periodicity of the lung function assessment was consid-
ered by most clinicians (76.0%) in the same time frame.
Discussion
This study was the first to explore the concept of asthma-
COPD overlap within the Portuguese medical community,
enabling a consensus regarding the need for the recognition
of an overlap entity. A significant number of participants and
the use of a Delphi method strengthened the study results.
After a final meeting, where all the results were discussed,
it was possible to reach a consensus over nomenclature,
classification criteria, treatment and orientation of these
patients.
The existence of patients who have at the same time
clinical characteristics of both asthma and COPD has been a
well-known fact for many decades,9,10 but only recently has
it begun to attract more attention.1--8 The need to define
this entity is something that is shared by most clinicians
who work in respiratory medicine. In our study, the majority
of the respondents to the first questionnaire (87.2%) con-
firmed this intention. However, there is still a lack of clear
and solid diagnostic criteria for this overlap which can be
used by all clinicians, an idea shared by most in our study
group (85.1%).
There have been a few guidelines, published in recent
years, proposing specific criteria for the diagnosis of the
asthma-COPD overlap entity. The first was created by the
Spanish group GesPOC in 2012,1 followed by the Finnish2 and
Czech guidelines3 with similar proposals. The Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD) and the
Global Initiative for Asthma (GINA) published a joint docu-
ment in 2014.4 A more recent consensus between specialists
from North America, Asia and Europe was also published.5
Although very recently a Portuguese meeting of experts in
respiratory medicine produced diagnostic recommendations
for ACOS,8 there was a need for a broader analysis using a
more accurate method for assessing the perspective of the
Portuguese medical society on the asthma-COPD overlap,
by recruiting a considerable number of clinicians in three
fields of Medicine (Immunoallergology, Family Medicine and
Pulmonology).
The designation of the overlap entity was one of
the points addressed in the first questionnaire. Most of
the clinicians chose between two of the most commonly
accepted names -- asthma-COPD overlap syndrome (ACOS)
and asthma-COPD overlap (ACO). Since the overlap between
these two chronic lung diseases is not really a syndrome or
a single disease, we believe that ACO should be the chosen
designation, which is in line with what is recommended by
the latest GOLD and GINA joint guideline on ACO.6
We can divide the diagnostic criteria into three
main categories: Clinical, Lung function and Laboratory
data/immune-inflammatory markers.
In terms of clinical criteria, the presence of simulta-
neous clinical characteristics of asthma and COPD in the
same patient was considered highly relevant and should be
listed, according to the majority of the clinicians, as a major
diagnostic criterion. This is in line with what is sustained in
several guidelines, such as the Spanish, Finnish and Czech,
although with some slight differences in some of them. Also
seen in most guidelines is the presence of a previous his-
tory of asthma and smoking history/exposure to biomass fuel
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Figure 1 Algorithm for the diagnosis of ACO.
One of the main concerns in clinical practice is to identify
which COPD patient would benefit from the use of ICS. This
is where the algorithm for ACO can play a role, and so it
seems more important that we have a diagnosis of COPD in
a patient that may also have a diagnosis of asthma or have
evidence of positivity on bronchodilation tests. The need
for having a COPD diagnosis is stated in a recent GesPOC and
GEMA algorithm.7 However, this diagnostic approach was not
assessed in our study, so we cannot comment on what the
clinician’s opinion would be on this.
On the other hand, other criteria such as a previous his-
tory of atopy and age ≥40 years were considered as minor
criteria.
Regarding lung function, almost all clinicians agreed that
the presence of a fixed airflow obstruction (FEV1/FVC < 0.7)
is highly relevant for the diagnosis of ACO and should be con-
sidered as a major criterion. This criterion is also present
in most of the guidelines. There is more heterogeneity in
terms of bronchodilation test positivity. In our Delphi, a pos-
itive bronchodilation test, with an increase in FEV1 of at
least 200 mL and 12%, and a positive bronchodilation test on
more than one occasion were considered highly relevant and
major criteria. A very positive bronchodilation test, with an
increase in FEV1 of 400 mL and at least 15%, was not con-
sidered as relevant, contrary to several guidelines, where
this is listed as a major criterion.1--3 By lowering the thresh-
old for the bronchodilation criteria we risk over diagnosing
COPD patients with ACO, and so it is important to register
the maintenance of these results on more than one occa-
sion for a more accurate ACO diagnosis. Although we might
have a more ‘‘definitive diagnosis’’ of ACO with a very posi-
tive bronchodilation test, we might be missing some patients
who could benefit from the use of ICS.
In terms of laboratory data/immune-inflammatory mark-
ers, the participants in our study did not consider any
of them as highly relevant or as major criteria. Periph-
eral eosinophilia, defined as >300 eosinophils/L or >5% of
leukocytes, and elevation of specific IgEs or positive skin
tests for common allergens, were the criteria that received
most consensus (>70% of the participants agreeing with
their inclusion) and should be considered as minor criteria.
Some guidelines considered the inclusion of an elevation of
total IgE and FENO as diagnostic criteria of ACO in a COPD
patient. FENO is an immune-inflammatory marker of increas-
ing importance and application, but the lack of established
cut-offs justifies the decision not to include this criterion in
the diagnostic algorithm. Also, the fact that it is not widely
available in many clinical settings limits its applicability.
However, in some cases, it might be taken into account in
order to help support the diagnosis.
The clinicians in our study considered a minimum of 2
major and one minor criteria for the diagnosis of ACO. In
most guidelines, the presence of a least 2 major or 2 minor
and 1 major is considered sufficient.
The definition of an algorithm for the diagnosis of
ACO was established after the final meeting of respira-
tory experts. It was assumed that this diagnosis should only
be considered in patients that have ‘‘simultaneous clini-
cal characteristics of asthma and COPD’’ and ‘‘fixed airflow
obstruction (FEV1/FVC < 0.7)’’. As a result, these two crite-
ria must always be present and do not count as major
criteria. The diagnostic algorithm can be seen in Fig. 1. The
proposed criteria for establishing the diagnosis of ACO are
listed in Table 2.
Concerning treatment, most clinicians agreed that ACO
should have a specific therapeutic approach. The combina-
tion of ICS with LABA or LAMA was considered the first line of
treatment by the majority, and the use of triple therapy with
ICS plus LABA and LAMA in more severe or symptomatic cases
(Table 3). Although there is still a lack of scientific evidence
to support these choices, there seems to be some consensus
on this subject with the use of ICS plus LABA or triple therapy
being recommended by the majority of the guidelines.1--8
The use of ICS plus LAMA was also considered as a valid
first-line therapeutic option by a considerable number of
clinicians. This differs from what is recommended by most
consensus documents1--8 but could be a plausible choice and
should be the subject of future interventional studies on ACO
patients.
Non-pharmacological treatment also plays a very impor-
tant role in ACO patients and this was stressed by the
clinicians in this study. Smoking cessation, pulmonary
rehabilitation, pneumococcal and influenza vaccination,
reinforcement of the therapeutic adhesion, verification of
the inhalation technique and comorbidities treatment were
considered key components in the management of these
patients. The importance of these measures has a very high
consensus in the medical community and is present in most
guidelines, not only for ACO but also for COPD or asthma.
The place for initial assessment and clinical orientation
of ACO patients was also evaluated in this study. Clinician’s
answers were divided between a specialist hospital clinic
and primary healthcare on the subject of initial diagnos-
tic medical approach and follow-up. The latter option was
mainly considered by Family Medicine specialists, which
might be a bias since the majority of them had a clinical
focus on chronic airway diseases and might not correspond
to the overall reality of Family Medicine practice in Portu-
gal. Moreover, in settings with a lack of diagnostic resources,
there might be a more consensual need for a hospital
referral. Additionally, we believe that a patient with a
symptomatic or severe ACO should also be referred to a spe-
cialist. Although there is no established definition on what
constitutes severe ACO, we suggest following the national
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Table 2 Criteria for the diagnosis of ACO.
Major Minor
Clinical criteria Previous history of asthma X
Presence of a previous history of smoking exposure and/or
exposure to biomass combustion
X
History of atopy X
Age ≥40 years X
Lung function criteria Positive bronchodilation test (increase in FEV1 of at least
200 mL and 12%) in more than 1 occasion
X
Laboratory data Peripheral eosinophilia (>300 eosinophils/L or >5% of
leukocytes)
X
Elevation of specific IgEs or positive skin tests for common
allergens
X
Table 3 Proposed treatment for a patient with the diagnosis of ACO.
First-line Second-line (in more severe or symptomatic cases;
no response to first line)
Pharmacological treatment ICS with LABA or LAMA ICS plus LABA and LAMA
ICS -- inhaled corticosteroid; LABA -- long-acting beta2-agonist; LAMA -- long-acting muscarinic antagonist.
recommendations for hospital referral in asthma and COPD
patients.11,12 Regarding the periodicity of clinical and lung
function evaluation, according to the majority of the clini-
cians, it should be performed every 3--6 months in the early
phase, and then adapted to the patient’s clinical severity
and symptoms.
This Delphi survey is the first one to analyze the opinion
on asthma/COPD overlap of the Portuguese medical commu-
nity. The fact that we have clinicians from different medical
specialties, who manage patients with respiratory condi-
tions, enables us to have a broader understanding of this
entity. This is also one of the largest studies, in terms of num-
ber of participants, on this subject, which strengthens the
relevance of the results. The use of a Delphi methodology
also enabled to access the different items more accurately,
in a step by step approach.
The fact that we had a rather low participation in the first
questionnaire, probably because of its open ended based
questions, and the lack of mandatory consecutive answers
to all the questionnaires, are weaknesses of this study.
Conclusion
Asthma-COPD overlap has been a matter of interest and
debate in the last few years. Different criteria and diagnos-
tic algorithms were proposed for establishing the diagnosis
of ACO. However, there is a lack of consensus regarding
this issue. This study had a nationwide participation of
clinicians from different medical specialties that manage
patients with chronic obstructive airways diseases. It was
clear that the information previously available regarding this
entity was not sufficient for their daily clinical practice and
there was a general agreement about the need to define
ACO. Based on the Delphi method, sequential steps of a
set of questionnaires were applied and analyzed in order
to establish diagnostic criteria and an algorithm for the
approach of ACO, adapted to our national context.
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